Prescription status of medicinal ingredients for human use (ICS: 11.120; HS 3004.90)

Notice of Consultation: Adding melatonin for sleep-related use in the pediatric population to the Prescription Drug List; (4 page(s), in English), (4 page(s), in French)

The purpose of this Notice of Consultation is to provide an opportunity for the public and other interested stakeholders to comment on the proposal to revise the listing for "Melatonin or its salts" on the human use part of the Prescription Drug List (PDL). Specifically, the proposal is to broaden the qualifier to capture all sleep-related uses in the pediatric population (i.e., all children and adolescents under 18 years of age).